Valsartan Lawyers To Be Appointed to Leadership Roles

Valsartan Lawyers To Be Appointed to Leadership Roles

Introduction

A case management order issued on April 2, by Judge Robert B. Kugler, presiding over federal valsartan lawsuits, called for leadership counsel to send a notice to all plaintiffs' attorneys asking if they are willing to join the plaintiffs’ leadership committees. Responses are supposed to be submitted at the earliest by April 18, and the list of nominated members must be submitted by April 22. At the next status conference scheduled for April 24, Judge Kugler will consider the final submitted list of valsartan lawyers.

There are nearly 50 product liability lawsuits filed against generic valsartan drug manufacturers and distributors alleging that the hypertension drug, which was distributed all these years, was contaminated with cancer-causing chemicals including N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA). The complaints filed claimed that these chemicals are linked to liver cancer, kidney cancer, colon cancer, stomach cancer, and other digestive tract cancers.